Ezetimibe Plus Moderate-dose Simvastatin after Acute Coronary Syndrome: What Are We IMPROVEing On?

American Journal of Medicine

Volumn 128, Issue 8, 2015, Pages 914.e1-914.e4

  DiNicolantonio, James J ^a   Chatterjee, Subhankar ^b   Lavie, Carl J ^c   Bangalore, Sripal ^d   O'Keefe, James H ^a,e  

^a SAINT LUKE S MID AMERICA HEART INSTITUTE   (United States)

^b R G KAR MEDICAL COLLEGE   (India)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

Acute coronary syndrome; Ezetimibe; Simvastatin; Statin

Indexed keywords

ATORVASTATIN; EZETIMIBE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; ROSUVASTATIN; SIMVASTATIN; AZETIDINE DERIVATIVE; DRUG COMBINATION; EZETIMIBE, SIMVASTATIN DRUG COMBINATION;

ACUTE CORONARY SYNDROME; CARDIOVASCULAR MORTALITY; CHOLESTEROL SYNTHESIS; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HIGH RISK PATIENT; HOSPITAL ADMISSION; HUMAN; MONOTHERAPY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; UNSTABLE ANGINA PECTORIS; DRUG COMBINATION; METHODOLOGY; TREATMENT OUTCOME;

ACUTE CORONARY SYNDROME; AZETIDINES; DRUG COMBINATIONS; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; SIMVASTATIN; TREATMENT OUTCOME;

EID: 84937814512     PISSN: 00029343     EISSN: 15557162     Source Type: Journal    
DOI: 10.1016/j.amjmed.2015.01.034     Document Type: Review

References (23)

1. J. Pekkanen, S. Linn, G. Heiss, and et al. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease N Engl J Med 322 24 1990 1700 1707
2. J. Tian, X. Gu, Y. Sun, and et al. Effect of statin therapy on the progression of coronary atherosclerosis BMC Cardiovasc Disord 12 2012 70
3. C. Baigent, L. Blackwell, J. Emberson, and et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials Lancet 376 9753 2010 1670 1681
4. E.A. Amsterdam, N.K. Wenger, R.G. Brindis, and et al. 2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 64 24 2014 e139 e228
5. N.J. Stone, J.G. Robinson, A.H. Lichtenstein, and et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 63 25 Pt B 2014 2889 2934
6. A.S. Wierzbicki The ezetimibe Jonah: the trials and tribulations of an unlucky drug Int J Clin Pract 65 12 2011 1207 1208
7. O'Riordan M. American Heart Association (AHA) 2014 Scientific Sessions. Conference News IMPROVE-IT: 'Modest' Benefit When Adding Ezetimibe to Statins in Post-ACS Patients. November 21, 2014. Available at: www.medscape.com/viewarticle/835030. Accessed March 5, 2015.
8. J.J. Kastelein, P.T. Sager, E. de Groot, and E. Veltri Comparison of ezetimibe plus simvastatin versus simvastatin monotherapy on atherosclerosis progression in familial hypercholesterolemia. Design and rationale of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial Am Heart J 149 2 2005 234 239
9. P.P. Toth, C.M. Ballantyne, M.H. Davidson, and et al. Changes in prescription patterns before and after reporting of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression trial (ENHANCE) results and expected effects on low-density lipoprotein-cholesterol reduction J Clin Lipidol 6 2 2012 180 191
10. J.S. Ross, S.G. Frazee, S.B. Garavaglia, and et al. Trends in use of ezetimibe after the ENHANCE trial, 2007 through 2010 JAMA Intern Med 174 9 2014 1486 1493
11. M. Miller, J.J. DiNicolantonio, M. Can, and et al. The effects of ezetimibe/simvastatin versus simvastatin monotherapy on platelet and inflammatory biomarkers in patients with metabolic syndrome Cardiology 125 2 2013 74 77
12. J.J. DiNicolantonio, A.K. Niazi, C.J. Lavie, and et al. The pros and cons of intensive statin therapy: a review of the literature J Clin Trial Res 2015 In press
13. C.J. Lavie, and R.V. Milani High-dose atorvastatin in acute coronary and cerebrovascular syndromes JACC Cardiovasc Interv 3 3 2010 340 342
14. G.G. Schwartz, A.G. Olsson, M.D. Ezekowitz, and et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial JAMA 285 13 2001 1711 1718
15. T.R. Pedersen, O. Faergeman, J.J. Kastelein, and et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial JAMA 294 19 2005 2437 2445
16. K. Josan, and F.A. McAlister Cholesterol lowering for secondary prevention: what statin dose should we use? Vasc Health Risk Manag 3 5 2007 615 627
17. C.P. Cannon, E. Braunwald, C.H. McCabe, and et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes N Engl J Med 350 15 2004 1495 1504
18. P. Deedwania, P.H. Stone, C.N. Bairey Merz, and et al. Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease: results of the Study Assessing Goals in the Elderly (SAGE) Circulation 115 6 2007 700 707
19. G. Di Sciascio, G. Patti, V. Pasceri, and et al. Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) Randomized Trial J Am Coll Cardiol 54 6 2009 558 565
20. C.J. Lavie, J.J. Dinicolantonio, R.V. Milani, and J.H. O'Keefe Niacin therapy lives for another day-maybe? J Am Coll Cardiol 61 21 2013 2197 2198
21. Husten L. The fate of new cholesterol drugs depends on IMPROVE-IT. Available at: http://www.forbes.com/sites/larryhusten/2013/11/15/the-fate-of-new-cholesterol-drugs-depends-on-improve-it. Accessed November 23, 2014.
22. J. Steinberger, and S.R. Daniels Obesity, insulin resistance, diabetes, and cardiovascular risk in children: an American Heart Association scientific statement from the Atherosclerosis, Hypertension, and Obesity in the Young Committee (Council on Cardiovascular Disease in the Young) and the Diabetes Committee (Council on Nutrition, Physical Activity, and Metabolism) Circulation 107 10 2003 1448 1453
23. H.N. Ginsberg, M.B. Elam, L.C. Lovato, and et al. Effects of combination lipid therapy in type 2 diabetes mellitus N Engl J Med 362 17 2010 1563 1574